-
Article
Open AccessImpact of osteoporosis and osteoporosis medications on fracture healing: a narrative review
Antiresorptive medications do not negatively affect fracture healing in humans. Teriparatide may decrease time to fracture healing. Romosozumab has not shown a beneficial effect on human fracture healing.
-
Article
Open AccessEstimating the economic burden of osteoporotic fractures in a multinational study: a real-world data perspective
Fracture-related costs vary by country. A standardized methodology and presentations were proposed to fairly assess the economic burden of osteoporotic fracture. Results indicated substantial costs of osteopor...
-
Article
Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement
-
Article
Open AccessIs it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group
The IOF Epidemiology and Quality of Life Working Group has reviewed the potential role of population screening for high hip fracture risk against well-established criteria. The report concludes that such an ap...
-
Article
The global approach to rehabilitation following an osteoporotic fragility fracture: A review of the rehabilitation working group of the International Osteoporosis Foundation (IOF) committee of scientific advisors
To conduct a review of the current state of the evidence for rehabilitation strategies post-fragility fracture.
-
Article
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
This study assessed the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japan, using bone mineral density (BMD) ...
-
Article
Harmonization of commercial assays for PINP; the way forward
International Federation of Clinical Chemistry and Laboratory Medicine and The International Osteoporosis Foundation Joint Committee on Bone Metabolism believes that the harmonization of PINP assays is an achi...
-
Article
Fracture risk following intermission of osteoporosis therapy
Given the widespread practice of recommending drug holidays, we reviewed the impact of medication discontinuation of two common anti-osteoporosis therapies (bisphosphonates and denosumab). Trial evidence sugge...
-
Article
Open AccessRecommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
Economic evaluations are increasingly used to assess the value of health interventions, but variable quality and heterogeneity limit the use of these evaluations by decision-makers. These recommendations provi...
-
Article
Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS
This study used data from the International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) to estimate the quality of life (QoL) impact of fracture. Hip, vertebral, and distal forearm fra...
-
Article
Self-perception of fracture risk: what can it tell us?
In this study, we report that self-perception of fracture risk captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is associated with improved medicati...
-
Article
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician shoul...
-
Article
Sensitivity and specificity of radiographic characteristics in atypical femoral fractures
Using the American Society for Bone and Mineral Research Task Force case definition for atypical femoral fractures, sensitivity and specificity of radiographic fracture characteristics were calculated. Fractur...
-
Article
International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study
-
Article
Open AccessOsteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function
The purpose of this study was to evaluate the measurement properties of the Osteoporosis Assessment Questionnaire-Physical Functioning (OPAQ-PF). Based on this study, the OPAQ-PF has confirmed unidimensionalit...
-
Article
Open AccessThe clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group
Osteoporosis causes an elevated fracture risk. We propose the continued use of T-scores as one means for diagnosis but recommend that, alternatively, hip fracture; osteopenia-associated vertebral, proximal hum...
-
Article
Open AccessDevelopment of the osteoporosis assessment questionnaire—physical function (OPAQ-PF): an osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function
We have developed a short, patient-reported outcome questionnaire—the Osteoporosis Assessment Questionnaire—Physical Function (OPAQ-PF)—that assesses the impact of osteoporosis on physical function. OPAQ-PF co...
-
Article
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies
Ibandronate reduces the risk of vertebral and non-vertebral fractures versus placebo in postmenopausal women with osteoporosis. This analysis, in which fractures were reported as safety events, showed that lon...
-
Article
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study
Accurate patient risk perception of adverse health events promotes greater autonomy over, and motivation towards, health-related lifestyles.
-
Article
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®
The relationship between baseline Fracture Risk Assessment Tool (FRAX®) and treatment efficacy was evaluated using data from a pivotal phase 3 study. Relative risk of vertebral, nonvertebral, and all clinical ...
